London, England, Nov. 10, 2018– Cyberliver Ltd, a developer of cutting-edge solutions for liver care, today announced that Dr Gautam Mehta and team will present a poster at The Liver Meeting 2018 of the American Association for the Study of Liver Diseases held on Friday, November 9th through Tuesday, November 13th, at the Moscone North and South Convention Centre in San Francisco.

The poster is entitled “AlcoChange: A Pilot Study of a Smartphone Tool to Reduce Alcohol Consumption in Alcohol-Related Liver Disease (Poster #1398) ” and will be presented on Sunday, November 11 2018, between 8:00 AM and 5:30 PM at Moscone Center, Hall C – Poster Hall.

Dr Gautam Mehta, Clinical Lead of the study, Consultant and Senior Lecturer in Hepatology at Royal Free Hospital said: “We are delighted to be presenting this study at The Liver Meeting 2018. The data demonstrate the potential of digital tools like AlcoChange to help manage alcohol-related liver disease (ARLD).” The AlcoChange clinical study, which ran from spring 2015 to end of 2017 at Royal Free London NHS Trust, supported by The Health Foundation and led by Prof Kevin Moore and Dr Gautam Mehta, clearly demonstrated that a smartphone app/breathalyzer can be used for self-monitoring and for Behavior Change Interventions (BCIs) in patients with ARLD, with a clear ‘dose-response’ amongst compliant patients. “Smartphone apps are a scalable intervention to help maintain abstinence in ARLD”

Commenting on the study, Prof Rajiv Jalan, Clinician Scientist, Prof of Hepatology, Head of Liver Failure group at UCL, said “the data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life”

About Cyberliver:

Cyberliver is a company that focuses on delivering cutting-edge solutions for liver care via the use of innovative technology, based out of London, England, UK

About AlcoChange:

AlcoChange is a patented Smartphone App/Breathalyzer platform, allows the monitoring of craving, alcohol consumption, and breath alcohol, and provides motivational messaging in response to patient triggers.

Alcohol contributes to over 5% of deaths worldwide, and UK death rates from alcohol-related liver disease (ARLD) are rising. Ongoing alcohol use in ARLD leads to markedly increased mortality, however there are no effective pharmacological therapies for maintaining abstinence. Behaviour change interventions (BCIs) are effective psychological tools for reducing alcohol use, but are difficult to scale.

This project developed a smartphone app and breathalyser (AlcoChange), to:

facilitate self-monitoring and deliver BCIs in response to patient triggers

undertake an open-label pilot study of 60 patients with ARLD, to determine compliance with the app/breathalyser and changes in self-reported alcohol consumption.

AlcoChange was developed following feedback from alcohol service users. It allows monitoring of craving, alcohol consumption and breath alcohol, and provides motivational messaging in response to patient triggers.

The pilot study recruited inpatients/outpatients at the Trust with ARLD and recent alcohol use. Inclusion criteria were intent to maintain abstinence, and possession of a compatible phone. Exclusion criteria were Child-Pugh score >7, or inability to provide consent. The primary endpoint was self-reported alcohol use.

Patented Technology

We have put in years of Research and Development involving some of the brightest minds in the world of Healthcare, Design and Information Technology to create AlcoChange - The worlds first digital platform for alcohol remote monitoring. The team has worked tirelessly on every single aspect of AlcoChange to make sure it is available to you.

A lot of intelligence has been built into the AlcoChange solution including the cloud-based platform and the mobile apps apart from the device. Our technology is Patented and is built to make an impact in your life.